Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model - Top-Institutions - MDSpire

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

  • By

  • Sumit Bhattacharyya

  • Insug O-Sullivan

  • Joanne K. Tobacman

  • June 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Jesse Brown Veterans Affairs Medical Center
    Jesse Brown Veterans Affairs Medical Center

    Chicago, Illinois

    Key Differentiators

    • Oncology

  • #2

    Jackson Laboratories
    Jackson Laboratories

    Bar Harbor, Maine

    Key Differentiators

    • Oncology

  • #3

    UCLA Jonsson Comprehensive Cancer Center
    UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #4

    University of California, Los Angeles
    University of California, Los Angeles

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #5

    Medizinische Hochschule Hannover
    Medizinische Hochschule Hannover

    Hannover, Lower Saxony

    Key Differentiators

    • Oncology

Original Source(s)

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

  • by Sumit Bhattacharyya, Insug O-Sullivan, Joanne K. Tobacman

  • June 1, 2026

Related Content

Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential

Retraction: Chamaejasmin B decreases malignant characteristics of mouse melanoma B16F0 and B16F10 cells

  • April 30, 2026

A Novel Framework for Skin Lesion Classification Using Hierarchical Attention Stacked Ensemble and Matthews Correlation Coefficient Weighted Averaging